Karen Santiago - Bristol-Myers Squibb Senior Vice President Controller
President
Ms. Karen Murphy Santiago is appointed as Senior Vice President, Corporationrationrate Controller of the company effective February 15, 2018. She joined BristolMyers Squibb Company in 2003 and has served in multiple roles of increasing responsibility. Most recently, from 2012 to 2015 she served as Vice President, Finance for Global Manufacturing and Supply, from 2015 to 2016 as Vice President, Finance for US and Puerto Rico Commercial and since 2016 she was Vice President, Lead for Enabling Functions and Finance Transformation since 2018.
| Age | 47 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Phone | 212-546-4000 |
| Web | http://www.bms.com |
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Ameet Nathwani | Sanofi ADR | N/A | |
| James Bradner | Novartis AG ADR | 49 | |
| Patrick Vallance | GlaxoSmithKline PLC ADR | 57 | |
| Olivier Charmeil | Sanofi ADR | 55 | |
| Elias Zerhouni | Sanofi ADR | 65 | |
| MarieFrance Tschudin | Novartis AG ADR | 53 | |
| Bernhardt Zeiher | Astellas Pharma | N/A | |
| Kazuhiro Sako | Astellas Pharma | N/A | |
| Menelas Pangalos | AstraZeneca PLC | 56 | |
| Roger Connor | GlaxoSmithKline PLC ADR | N/A | |
| Yoshitsugu Shitaka | Astellas Pharma | N/A | |
| Kazuhiro Sako | Astellas Pharma | N/A | |
| Masatoshi Kuroda | Astellas Pharma | N/A | |
| Mark Mallon | AstraZeneca PLC | N/A | |
| Paul Hudson | AstraZeneca PLC ADR | N/A | |
| DavidAlexandre Gros | Sanofi ADR | 42 | |
| Phil Thomson | GlaxoSmithKline PLC ADR | N/A | |
| David Fredrickson | AstraZeneca PLC | N/A | |
| Leon Wang | AstraZeneca PLC | N/A | |
| Fiona Cicconi | AstraZeneca PLC | N/A | |
| Luke Miels | AstraZeneca PLC ADR | N/A | |
Bristol Myers Squibb Leadership Team
Elected by the shareholders, the Bristol-Myers Squibb's board of directors comprises two types of representatives: Bristol-Myers Squibb inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bristol-Myers. The board's role is to monitor Bristol-Myers Squibb's management team and ensure that shareholders' interests are well served. Bristol-Myers Squibb's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bristol-Myers Squibb's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ann Powell, Chief Human Resource Officer, Senior Vice President | ||
| Togo West, Independent Director | ||
| Karen Vousden, Director | ||
| Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics Officer | ||
| Alan Lacy, Independent Director | ||
| Robert Bertolini, Independent Director | ||
| Jose Baselga, Independent Director | ||
| Charles Bancroft, CFO, Executive Vice President | ||
| Gerald Storch, Independent Director | ||
| Louis Schmukler, President - Global Manufacturing and Supply | ||
| Michael Grobstein, Independent Director | ||
| Christopher Boerner, Executive Vice President and Chief Commercial Officer | ||
| John Elicker, Senior Vice President - Public Affairs and Investor Relations | ||
| Anne Nielsen, Senior Vice President Chief Compliance and Ethics Officer | ||
| Karen Santiago, Senior Vice President Controller | ||
| Giovanni Caforio, COO, Director | ||
| Vicki Sato, Independent Director | ||
| Emmanuel Blin, Senior Vice President Chief Strategy Officer | ||
| Joseph Caldarella, Senior Vice President Corporate Controller | ||
| Laurie Glimcher, Independent Director | ||
| Murdo Gordon, Executive Vice President Chief Commercial Officer | ||
| Lamberto Andreotti, CEO, Director | ||
| Thomas Lynch, Independent Director | ||
| Dinesh Paliwal, Independent Director | ||
| Lewis Campbell, Independent Director | ||
| Theodore Samuels, Independent Director | ||
| Samuel Moed, Senior Vice President - Strategic Planning and Analysis | ||
| Matthew Emmens, Independent Director | ||
| Ann Judge, Senior Vice President - Global Human Resources | ||
| Sandra Leung, General Counsel, Corporate Secretary | ||
| Paul Autenried, Senior Vice President - Enterprise Services, CIO | ||
| Francis Cuss, Executive Vice President Chief Scientific Officer | ||
| Paul Biondi, Senior Vice President Head - Business Development | ||
| Peter Arduini, Independent Director |
Bristol-Myers Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bristol-Myers Squibb a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Revenue | 46.38 B | |||
| EBITDA | 20.1 B | |||
| Net Income | 7.01 B | |||
| Cash And Equivalents | 6.07 B | |||
| Cash Per Share | 3.72 X | |||
| Total Debt | 39.6 B | |||
| Debt To Equity | 59.40 % | |||
| Current Ratio | 1.40 X | |||
| Book Value Per Share | 7.55 X | |||
| Cash Flow From Operations | 16.21 B |
Pair Trading with Bristol-Myers Squibb
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol-Myers Squibb position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol-Myers Squibb will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to O I could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace O I when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back O I - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling O I Glass to buy it.
The correlation of O I is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as O I moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if O I Glass moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for O I can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Bristol-Myers Pink Sheet
If you are still planning to invest in Bristol Myers Squibb check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bristol-Myers Squibb's history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |